open access

Vol 14, No 2 (2018)
Guidelines / Expert consensus
Published online: 2018-04-26
Get Citation

Cancer in pregnant women

Editing: Maryna Rubach
DOI: 10.5603/OCP.2018 .0011
·
Oncol Clin Pract 2018;14(2):62-78.

open access

Vol 14, No 2 (2018)
GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT IN MALIGNANT NEOPLASMS 2018
Published online: 2018-04-26

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Cancer in pregnant women

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 2 (2018)

Article type

Guidelines / Expert consensus

Pages

62-78

Published online

2018-04-26

DOI

10.5603/OCP.2018 .0011

Bibliographic record

Oncol Clin Pract 2018;14(2):62-78.

Authors

Editing: Maryna Rubach

References (73)
  1. Peccatori FA, Azim HA, Orecchia R, et al. ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi160–vi170.
  2. Voulgaris E, Pentheroudakis G, Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg Oncol. 2011; 20(4): e175–e185.
  3. Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010; 46(18): 3158–3168.
  4. Amant F, Loibl S, Neven P, et al. Breast cancer in pregnancy. Lancet. 2012; 379(9815): 570–579.
  5. Loibl S, Han SN, Amant F. Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel). 2012; 7(3): 204–209.
  6. Nowecki Z. i wsp. Standardy postępowania diagnostyczno-terapeutycznego u kobiet w ciąży chorych onkologicznie. Inwazyjny rak piersi u ciężarnych zgłoszone do druku 10.2016.
  7. Calsteren KV, Verbesselt R, Devlieger R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer. 2010; 20(9): 1456–1464.
  8. Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol. 2010; 119(3): 594–600.
  9. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004; 5(5): 283–291.
  10. Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist. 2016; 21(5): 563–570.
  11. Pavlidis NA. Coexistence of Pregnancy and Malignancy. Oncologist. 2002; 7(4): 279–287.
  12. US Deprtm.of Health and Human Services. National Toxicology Program 2013 2013.
  13. Hahn KME, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006; 107(6): 1219–1226.
  14. Peccatori FA, Azim HA, Scarfone G, et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat. 2009; 115(3): 591–594.
  15. Zagouri F, Sergentanis TN, Chrysikos D, et al. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013; 121(2 Pt 1): 337–343.
  16. Krzakowski M. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013. In: Rubach M. ed. Nowotwory u kobiet w ciąży. Tom I. Via Media, Gdańsk 2013.
  17. Azim HA, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. Cancer Treat Rev. 2010; 36(2): 110–121.
  18. Lambertini M, Peccatori FA, Azim HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015; 41(4): 301–309.
  19. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008; 111(12): 5505–5508.
  20. Mazonakis M, Tzedakis A, Varveris C, et al. Radiotherapy for supradiaphragmatic Hodgkin's disease: determination of the proper fetal shielding conditions using Monte Carlo methodology. Phys Med. 2011; 27(4): 181–187.
  21. Rizack T, Mega A, Legare R, et al. Management of hematological malignancies during pregnancy. Am J Hematol. 2009; 84(12): 830–841.
  22. Bakkal BH, Sayin M. Radiotherapy and Pregnancy: Together or Alone. Derleme Review. 2012; 19(2): 120–127.
  23. Kourinou KM, Mazonakis M, Lyraraki E, et al. Photon-beam radiotherapy in pregnant patients: can the fetal dose be limited to 10 cGy or less? Phys Med. 2015; 31(1): 85–91.
  24. Nuyttens JJ, Prado KL, Jenrette JM, et al. Fetal dose during radiotherapy: clinical implementation and review of the literature. Cancer Radiother. 2002; 6(6): 352–357.
  25. Osei EK, Faulkner K. Radiation risks from exposure to diagnostic X-rays during pregnancy. Radiography. 2000; 6(2): 131–144.
  26. Poortman P, Kaidar-Person O, Masset H, Lampka E. Radiotherapy during pregnancy. Textbook of Cancer in Pregnancy 2017: 17–24.
  27. Skrzypczyk-Ostaszewicz A, Jagielska B, Śpiewankiewicz B, et al. Rak piersi współistniejący z ciążą. Curr Gynecol Oncol. 2014; 12(1): 14–24.
  28. Loibl S, Schmidt A, Gentilini O, et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol. 2015; 1(8): 1145–1153.
  29. Loibl S. Adjuvant therapy in patients with breast cancer during pregnancy. Cancer Treat Res. 2009; 151: 317–328.
  30. Toesca A, Gentilini O, Peccatori F, et al. Locoregional treatment of breast cancer during pregnancy. Gynecol Surg. 2014; 11(4): 279–284.
  31. Vrancken Peeters MJ, et al. Breast cancer during and after pregnancy. Eur J Cancer. 2010; 8: 31–32.
  32. Pieńkowski T, Skrzypczyk A. Ciąża i rak piersi. In: Dłużniewski M. ed. Ciąża - problemy internisty i kardiologa. Czelej 2012: 297–303.
  33. Amant F F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013; 31(20): 2532–2539.
  34. Al-Halal H, Kezouh A, Abenhaim HA. Incidence and obstetrical outcomes of cervical intraepithelial neoplasia and cervical cancer in pregnancy: a population-based study on 8.8 million births. Arch Gynecol Obstet. 2013; 287(2): 245–250.
  35. Azim HA, Botteri E, Renne G, et al. The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. Acta Oncol. 2012; 51(5): 653–661.
  36. Han SN, Mhallem Gziri M, Van Calsteren K, et al. Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies. Ther Adv Med Oncol. 2013; 5(4): 211–219.
  37. Paraskevaidis E, Koliopoulos G, Kalantaridou S, et al. Management and evolution of cervical intraepithelial neoplasia during pregnancy and postpartum. Eur J Obstet Gynecol Reprod Biol. 2002; 104(1): 67–69.
  38. Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012; 13(3): 256–264.
  39. Evens A, Lishner M, Avivi I, Poortmans P, Lampka E. Hodgkin Lymphoma and Non –Hodgkin Lymphoma. Textbook of Cancer in Pregnancy 2017: 111–118.
  40. Germann N, Haie-Meder C, Morice P, et al. Management and clinical outcomes of pregnant patients with invasive cervical cancer. Ann Oncol. 2005; 16(3): 397–402.
  41. Amant F, Halaska MJ, Fumagalli M, et al. ESGO task force ‘Cancer in Pregnancy’. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014; 24(3): 394–403.
  42. Giuntoli RL, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol. 2006; 49(3): 492–505.
  43. Machado F, Vegas C, Leon J, et al. Ovarian cancer during pregnancy: analysis of 15 cases. Gynecol Oncol. 2007; 105(2): 446–450.
  44. Patterson DM, Murugaesu N, Holden L, et al. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer. 2008; 18(1): 43–50.
  45. Zhao XY, Huang HF, Lian LJ, et al. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer. 2006; 16(1): 8–15.
  46. Ishioka Si, Hayashi T, Endo T, et al. Advanced epithelial ovarian carcinoma during pregnancy. Int J Clin Oncol. 2007; 12(5): 375–378.
  47. Behtash N, Karimi Zarchi M, Modares Gilani M, et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth. 2008; 8: 3.
  48. El-Messidi A, Patenaude V, Abenhaim HA. Incidence and outcomes of women with non-Hodgkin's lymphoma in pregnancy: a population-based study on 7.9 million births. J Obstet Gynaecol Res. 2015; 41(4): 582–589.
  49. Froesch P, Belisario-Filho V, Zucca E. Hodgkin and non-Hodgkin lymphomas during pregnancy. Recent Results Cancer Res. 2008; 178: 111–121.
  50. Lishner M, Zemlickis D, Degendorfer P, et al. Maternal and foetal outcome following Hodgkin's disease in pregnancy. Br J Cancer. 1992; 65(1): 114–117.
  51. Sagan D, Semczuk A, Lampka E. Combination chemotherapy for Hodgkin's lymphoma during pregnancy: favorable outcome for mother and child. J Obstet Gynaecol Res. 2010; 36(4): 882–886.
  52. Bachanova V, Connors JM. Hodgkin lymphoma in pregnancy. Curr Hematol Malig Rep. 2013; 8(3): 211–217.
  53. Avilés A, Neri N, Nambo MJ. Hematological malignancies and pregnancy: treat or no treat during first trimester. Int J Cancer. 2012; 131(11): 2678–2683.
  54. Pereg D, Koren G, Lishner M. The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy. Haematologica. 2007; 92(9): 1230–1237.
  55. Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008; 34(4): 302–312.
  56. El-Hemaidi I, Robinson SE. Management of haematological malignancy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2012; 26(1): 149–160.
  57. Avivi I, Farbstein D, Brenner B, et al. Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. Blood Rev. 2014; 28(5): 213–220.
  58. Vandenbriele C, Dierickx D, Amant F, et al. The treatment of hematologic malignancies in pregnancy. Facts Views Vis Obgyn. 2010; 2(2): 74–87.
  59. Rizack T, Mega A, Legare R, et al. Management of hematological malignancies during pregnancy. Am J Hematol. 2009; 84(12): 830–841.
  60. Roh M, Eliades P, Gupta S, et al. Cutaneous melanoma in women. Int J Womens Dermatol. 2015; 1(1): 21–25.
  61. Boussios S, Pentheroudakis G. Managing Cancer During Pregnancy. Springer 2016: 123–134.
  62. Kocian P, Lampka E, Stec R. Gastro-intestinal cancer. Textbook Cancer in Pregnancy 2017: 125–130.
  63. Sakamoto K, Kanda T, Ohashi M, et al. Management of patients with pregnancy-associated gastric cancer in Japan: a mini-review. Int J Clin Oncol. 2009; 14(5): 392–396.
  64. Boussios S, Han SN, Fruscio R, et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013; 82(3): 499–505.
  65. Mitrou S, Petrakis D, Fotopoulos G, et al. Lung cancer during pregnancy: A narrative review. J Adv Res. 2016; 7(4): 571–574.
  66. Ali S, Jones GL, Culligan DJ, et al. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol. 2015; 170(4): 487–495.
  67. Chang A, Patel S. Treatment of acute myeloid leukemia during pregnancy. Ann Pharmacother. 2015; 49(1): 48–68.
  68. Kozakiewicz B. Nowotwory złośliwe u kobiet w ciąży. PZWL 2017: 111–113.
  69. Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol. 2015; 94 Suppl 2: S167–S176.
  70. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016; 175(1): 31–36.
  71. Avivi I, Lishner M. Acute leukemia during pregnancy. Textbook of Cancer in Pregnancy : 105–109.
  72. Zaouri F, Maniou I. Managing Cancer During Pregnancy. Springer 2016: 89–95.
  73. Lambertini M, Skrzypczyk-Ostaszewicz A. Supportive therapy. Textbook Cancer in Pregnancy 2017: 39–45.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl